More Questions than Answers at Gene Editing Summit
By Chloe Poston,
Genes to Genomes
| 12. 09. 2015
[cites CGS' Marcy Darnovsky]
Last week, the National Academies of Science and Engineering joined forces with the Chinese Academy of Science and the Royal Society of the United Kingdom to host an International Summit on Human Gene Editing in Washington, DC. Top scholars in genetics, bioengineering, ethics, and law debated the merits of human gene editing; however consensus was far from achieved. In fact, the repeated reminders of “unknown unknowns” and references to Brave New World left participants wondering how such disparate opinions could be formed into a single set of guidelines from the summit organizing committee.
The final statement from the organizing committee, released at the conclusion of the summit, signified that this gathering would not be the place where final decisions were made. Instead, the committee used the three days of insightful perspectives to develop a framework for how information should be collected. The point of the summit was not to answer the looming questions surrounding human gene editing; rather, it was to determine what questions to ask—and of whom—in order to begin developing recommendations on how to move forward with this technology.
The mix of...
Related Articles
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...
By Amy Feldman, Forbes | 02.17.2026
"Jennifer Doudna" by Duncan Hull for the Royal Society via Wikimedia Commons licensed under CC by SA 3.0
Soon after KJ Muldoon was born in August 2024, he was lethargic and wouldn’t eat. His worried doctors realized his ammonia...
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...